Comparative effectiveness of bioresorbable vascular scaffold stents versus other drug-eluting stents for the treatment of coronary artery disease
HAYES, Inc.
Record ID 32016000973
English
Authors' recommendations:
Drug-eluting stents (DES) have rapidly become the standard of care for patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI), but due to the permanent presence of the metallic stent frame in the coronary vessel wall, complications such as late restenosis and stent thrombosis can arise. The Absorb Bioresorbable Vascular Scaffold (BVS) (Abbott Vascular) is an everolimus-eluting stent comprised of a poly-L-lactide scaffold that completely resorbs over a time period of 2 to 3 years, thus avoiding chronic issues inherent in a permanent metallic DES. Controversy: In addition to providing the same drug delivery benefits as metallic DES, BVS provides temporary mechanical support to the vessel wall without permanently caging it, thus potentially circumventing many limitations associated with a permanent metallic DES implant, such as late restenosis and stent thrombosis, jailing of artery side branches, and elimination of late surgical options. Fully resorbable BVS offers a new PCI option for CAD patients; however, the effectiveness and safety of BVS compared with permanent metallic DES remain unclear.
Relevant Questions: How do BVS stents compare with other stent types for reducing death, myocardial infarction, repeat revascularizations, and improving symptoms in patients with CAD? How do BVS stents compare with other stent types with respect to safety? Have definitive patient selection criteria been established for the use of BVS stents?
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=46286
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Coronary Artery Disease
- Drug-Eluting Stents
- Stents
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.